checkAd

     104  0 Kommentare Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021

    Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET to announce its next clinical product candidates.

    Gossamer management will present and discuss its forthcoming additions to its clinical product candidate pipeline. As part of the event, Gossamer Bio management will be available for questions.

    Conference Call and Webcast

    Gossamer will host a conference call and live audio webcast at 2:30 pm ET on Monday, October 11. The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:

    Conference ID: 4165598
    Domestic Dial-in Number: (833) 646-0603
    International Dial-in Number: (929) 517-9782
    Live Webcast: https://edge.media-server.com/mmc/p/4jha6kh9

    A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.

    About Gossamer Bio

    Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will …

    Schreibe Deinen Kommentar

    Disclaimer